In 2019, a startup called Ambrosia began charging customers $8,000 for a liter of plasma from donors under 25, promising rejuvenation. The FDA responded with an extraordinary public statement: there is “no proven clinical benefit” to young blood plasma infusions, and the agency was “deeply concerned” about clinics exploiting patients. Ambrosia paused operations. But the underlying science — parabiosis research that genuinely shows remarkable effects in animal models — didn’t pause. And the longevity community continues to argue over what it means.
The Parabiosis Experiments: What They Actually Showed
The modern parabiosis story begins with experiments that seem lifted from science fiction. In parabiosis, two animals are surgically joined so that they share a circulatory system — literally sharing blood. When researchers in the 1950s first joined old and young mice in this way, they observed something startling: the old mice showed improvements in tissue regeneration and physical function, while the young mice appeared to age faster.
The field was largely dormant until the 2000s and 2010s, when researchers including Amy Wagers and Tony Wyss-Coray at Stanford revived it with more sophisticated tools. Their experiments confirmed and extended the earlier findings: old mice connected to young mice showed improved muscle regeneration, better learning and memory, and even some reversal of cardiac aging. The young mice showed accelerated brain aging.
Crucially, some of these effects appeared to persist after the animals were separated, suggesting it wasn’t just about current blood composition but about signals that triggered longer-lasting changes. Even more significantly, some benefits could be replicated by simply injecting young blood plasma (without the cells) into old mice — pointing toward soluble factors rather than young blood cells as the active agents.
Key fact: A 2014 paper in Nature Medicine found that injecting young mouse blood into old mice improved cognitive performance in spatial memory tasks, with improvements in synaptic plasticity in the hippocampus — the brain’s primary memory structure.
The Search for Active Factors: GDF11, GPLD1, and the Complexity Problem
Naturally, researchers tried to identify which specific factors in young blood were responsible for the rejuvenating effects. GDF11 (Growth Differentiation Factor 11) received enormous early attention after a 2013 Cell paper suggested it reversed cardiac and skeletal muscle aging in mice. GDF11 levels decline with age, and restoring them appeared to restore youthful function.
The GDF11 story subsequently became complicated — perhaps the most instructive cautionary tale in parabiosis research. A competing group published data suggesting that GDF11 actually increased with age rather than decreased, and that it might impair rather than improve muscle regeneration. A protracted scientific dispute followed, and the consensus remains unsettled. This illustrates a fundamental challenge: blood is extraordinarily complex, carrying thousands of proteins, metabolites, and signaling molecules that change with age in different directions, with different tissue-specific effects.
More recent work has identified other candidates, including GPLD1 (a liver enzyme that declines with exercise but increases in young blood), clusterin, and platelet-derived factors as potential contributors to young blood effects. The picture that emerges is not a single “young blood factor” but a complex mixture of pro-aging factors that increase with age and anti-aging factors that decrease — suggesting that removing the bad may be as important as adding the good.
Commercial Clinics, Plasma Infusions, and Regulatory Push-Back
The commercial landscape for young plasma infusions has been chaotic. Multiple clinics in the US began operating after initial parabiosis excitement, typically sourcing plasma from blood banks with young donors and charging premium prices for what is essentially an unapproved experimental treatment. The clinical evidence they offered was anecdotal or from small, uncontrolled observational studies — essentially testimonials dressed in medical language.
The FDA’s 2019 statement was unusually direct. The agency noted that plasma infusions from young donors are not FDA-approved for any longevity or anti-aging purpose, that they carry real risks (transfusion reactions, TRALI — transfusion-related acute lung injury, infectious disease transmission, volume overload), and that companies marketing them as anti-aging treatments were engaging in deceptive practices. This wasn’t a ban on the research — it was a warning against commercial exploitation.
Ethical Dimensions: Who Bears the Cost?
Beyond safety and efficacy, young blood transfusions raise ethical questions that don’t arise with most longevity interventions. Plasma donation is not entirely without risk or burden to donors. A scenario where wealthy older individuals systematically pay younger, less-wealthy individuals for their plasma to support anti-aging experiments carries uncomfortable resonances — a form of biological wealth transfer that has prompted genuine ethical debate among bioethicists.
The concern is not that plasma donation is inherently exploitative (it’s regulated and voluntary), but that a multi-billion-dollar industry built on the premise that young blood extends elite lifespans would create structural pressures and incentives that deserve scrutiny.
Where the Legitimate Science Is Going
Serious researchers in the parabiosis field have largely moved away from whole plasma transfusions toward identifying specific factors — both activating beneficial ones and inhibiting pro-aging ones. The concept of “young blood” as a consumer product has largely been discredited in mainstream geroscience. What remains is a genuinely rich scientific question about circulating signals and systemic aging that is being actively researched through more rigorous methods.
At lifespan.asia, we follow the systems biology of aging — including the cutting-edge research on circulating factors, blood-based biomarkers, and what the parabiosis literature really tells us about systemic aging. The animal results are fascinating; the commercial applications are premature. Follow our coverage to understand the difference.